Roscovitine
别名: CYC202, Seliciclib, R-roscovitine
目录号:S1153 Purity: 99.85%
Roscovitine是一种有效的,选择性CDK抑制剂,作用于Cdc2,CDK2和CDK5时,无细胞试验中IC50分别为0.65 μM,0.7 μM和0.16 μM,对CDK4/6几乎没有作用。Phase 2。
CAS: 186692-46-6
客户使用Selleck的Roscovitine发表文献124篇
- Cell, 2023 186(21):4694-4709.e16
- Signal Transduct Target Ther, 2020 5(1):197
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Cell, 2018 10.1016/j.cell.2018.11.011
- Cell, 2018 174(5):1127-1142
- Gut, 2017 66(8):1358-1368
- Cell, 2014 20;159(5):1126-1139.
- J Hematol Oncol, 2014 7(1):53
- Cell, 2013 155(5):1088-103
- Circ Res, 2012 111(2):201-11
- Nucleic Acids Res, 2024 gkae807
- Transl Cancer Res, 2024 13(4):1876-1886
- Cell Genom, 2024 4(2):100487
- Nat Commun, 2023 14(1):6322
- Nat Commun, 2023 14(1):3213
- Int J Mol Sci, 2023 24(8)7009
- Front Oncol, 2023 13:1251297
- J Cell Sci, 2023 136(4)jcs259788
- Nat Commun, 2022 13(1):668
- Bone Res, 2022 10(1):33
- Cell Death Dis, 2022 13(11):966
- Cell Rep, 2022 41(8):111679
- Cells, 2022 11(21)3344
- BMC Biol, 2022 20(1):115
- Exp Neurol, 2022 S0014-4886(22)00048-6
- Cancers (Basel), 2022 14(19)4727
- Biomedicines, 2022 10(2)404
- Biochim Biophys Acta Gene Regul Mech, 2022 1865(8):194887
- Sci Rep, 2022 12-1:16810
- Sci Adv, 2022 8(31):eabo0412
- Nucleic Acids Res, 2021 49(13):7492-7506
- EMBO J, 2021 e99692
- Life Sci, 2021 269:119062
- Int J Mol Sci, 2021 22(17)9648
- Front Cell Dev Biol, 2021 9:662868
- Toxicol Lett, 2021 341:68-79
- Nat Commun, 2020 11(1):4027
- Oncogene, 2020 10.1038/s41388-020-01403-y
- Elife, 2020 7;9:e44571
- J Mol Cell Biol, 2020 12(8):644-653
- Front Cell Dev Biol, 2020 8:845
- Mol Cell Biol, 2020 40(4)
- Bone, 2020 131:115153
- PLoS One, 2020 15(6):e0234708
- J Biomater Sci Polym Ed, 2020 1-10
- J Pain Res, 2020 13:2113-2124
- Reprod Domest Anim, 2020 55(3):351-363
- Mol Cell, 2019 73(4):670-683.e12
- J Exp Med, 2019 216(12):2819-2837
- EMBO J, 2019 38(19):e101704
- J Exp Clin Cancer Res, 2019 38(1):322
- J Exp Clin Cancer Res, 2019 38(1):463
- Cancer Res, 2019 10.1158/0008-5472.CAN-18-3374
- Proc Natl Acad Sci U S A, 2019 116(37):18561-18570
- PLoS Biol, 2019 17(8):e3000203
- Oncogene, 2019 38(25):4948-4961
- J Cell Biol, 2019 218(7):2113-2123
- J Cell Biol, 2019 218(9):2865-2875
- Front Immunol, 2019 10:1554
- Neurobiol Dis, 2019 126:47-61
- Mol Cancer Ther, 2019 18(9):1520-1532
- J Virol, 2019 93(3)e01803-18
- Cancers (Basel), 2019 11(11)
- ACS Chem Neurosci, 2019 10(4):1992-2003
- J Neurochem, 2019 10.1111/jnc.14827
- Development, 2019 146(23)dev182519
- Toxicol Sci, 2019 10.1093/toxsci/kfz135
- Reprod Fertil Dev, 2019 31(3):473-481
- Nat Commun, 2018 9(1):3613
- Nat Commun, 2018 9(1):2678
- Mol Cell, 2018 71(1):117-128
- Mol Cell, 2018 69(3):371-384
- Nucleic Acids Res, 2018 46(20):10724-10739
- Proc Natl Acad Sci U S A, 2018 115(8):1913-1918
- Br J Cancer, 2018 118(6):e13
- Cell Rep, 2018 25(9):2605-2616
- Am J Pathol, 2018 188-10:2356-2368
- Biochem Pharmacol, 2018 156:22-31
- J Mol Cell Biol, 2018 10.1093/jmcb/mjy033
- J Cancer, 2018
- Toxicol Lett, 2018 296:125-131
- Kidney Blood Press Res, 2018 43(2):616-627
- Nat Commun, 2017 1;8(1):1232
- Mol Cell, 2017 68(1):185-197
- Nucleic Acids Res, 2017 45(16):9441-9454
- Dev Cell, 2017 41(3):274-286
- Cancer Res, 2017 77(9):2512-2521
- Cancer Res, 2017 77(17):4567-4578
- Cancer Res, 2017 77(23):6614-6626
- Haematologica, 2017 102(5):826-834
- Oncogene, 2017 36(26):3781-3788
- Aging Cell, 2017 16(3):575-584
- Oncotarget, 2017 8(63):107206-107222
- Front Cell Neurosci, 2017 11:281
- Cell Signal, 2017 39:74-83
- Sci Rep, 2017 7:43517
- PLoS One, 2017 12(8):e0181601
- Neuroscience, 2017 351:24-35
- PPAR Res, 2017 2017:4313561
- Exp Ther Med, 2017 13(5):2169-2176
- Cell Biochem Biophys, 2017 75(1):119-129
- Nat Commun, 2016 7:12880
- Cell Death Dis, 2016 7(11):e2459
- Oncogene, 2016 10.1038/onc.2016.247
- Mol Cell Proteomics, 2016 15(10):3203-3219
- Mol Cancer Ther, 2016 15(6):1332-43
- Oncotarget, 2016 7(23):34785-99
- Cell Cycle, 2016 15(20):2742-52
- Mol Med Rep, 2016 14(2):1083-90
- Nucleic Acids Res, 2015 43(20):9788-803
- Dev Cell, 2015 33(6):703-16
- Oncogene, 2015 34(34):4460-70
- dspace, 2015
- Nat Commun, 2014 5:5637
- Cancer Lett, 2014 356(2 Pt B):656-68
- Br J Pharmacol, 2014 171(24):5757-73
- Br J Cancer, 2013 110(2):510-9
- J Cell Biol, 2013 201(7):997-1012
- Mol Pharm, 2013 10(12):4620-8
- J Biol Chem, 2013 288(36):25924-37
- Cell Cycle, 2013 12(23):3689-701
- Br J Cancer, 2012 106(3):482-9
- J Neurosci, 2012 32(32):11050-66
化学信息&溶解度
分子量 | 354.45 |
分子式 | C19H26N6O |
CAS号 | 186692-46-6 |
Smiles | CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 71 mg/mL ( 200.31 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 71 mg/mL Water : Insoluble DMSO : 71 mg/mL ( 200.31 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 71 mg/mL Water : Insoluble DMSO : 71 mg/mL ( 200.31 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 31 mg/mL Water : Insoluble DMSO : 71 mg/mL ( 200.31 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 71 mg/mL Water : Insoluble DMSO : 71 mg/mL ( 200.31 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 71 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:10mg/ml
(28.21mM)
操作示例:以 1 mL 工作液为例,取50μL200mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。